Grade of malignancy of a diagnosed cancer is the central concern for both patients and their physicians. Grade is used to determine the intensity of the required cancer treatment. Particularly in the case of prostate cancer, the disease can take widely varying courses in different patients. Therefore, cancer researchers have been looking for measurable, reliable biomarkers that give clues about the aggressiveness of a tumor in order to choose an appropriate therapy.
In many types of cancer, alterations in a tumor's genetic material indicate how dangerous the cancer is. Prostate cancer, however, exhibits far fewer of these mutations than other cancer types. "We have therefore suspected that prostate cancer is driven primarily by alterations in epigenetic characteristics, that is, chemical changes in the genetic material that do not affect the sequence of DNA building blocks," says Prof. Christoph Plass from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), who is one of the project leaders in the current publication.
Quiz on Prostate Cancer
Prostate cancer is fast gaining as a common cancer form among men; more threatening since its symptoms often go unnoticed until it's too late. This quiz tests your knowledge on prostate cancer, its diagnosis and treatment options and is as mandatory for men as the screening tests mentioned here are!
Advertisement
For a long time, the means by which epigenetic patterns in the DNA of cancer cells undergo changes have remained a mystery. Scientists have discovered specific cellular proteins that can have a major influence on such patterns. A network of researchers from the German Cancer Research Center (DKFZ), the University of Zurich, Hamburg-Eppendorf University Hospital, Heidelberg University, and other institutes have been searching for regulatory proteins that change the epigenetic characteristics of prostate cancer cells and may thus have an impact on the course of the disease.
In a first step, the scientists searched databases containing molecular information on a large number of prostate cancer cases. Using these data, they investigated whether a particular, known epigenetic regulatory protein is expressed in tumor cells at significantly higher or lower levels than in healthy cells from the same patient.
![Prostate Cancer - Animation]( "Prostate Cancer - Animation")
The researchers found the most obvious differences in the expression of a protein called BAZ2A. "The normal known function of this protein is to suppress factories that produce cellular proteins and thus affect the viability of cells," says Prof. Roland Eils, who leads a research group at both the DKFZ and at Heidelberg University. "But when we turned off BAZ2A in the cell lines of metastasizing prostate cancer, their growth was paradoxically slowed." Further studies showed that higher levels of BAZ2A increased specific malignant properties of prostate cancer cells, including their mobility and capacity to invade surrounding tissue. A detailed molecular analysis of prostate cancer cells showed that the overproduction of BAZ2A led to alterations in epigenetic patterns which then inhibited the activity of a number of cancer-suppressing genes. The scientists therefore suspected that the overexpression of BAZ2A might have a direct impact on the malignancy of prostate cancer and thus serve as a predictor for the course of the disease.
The team investigated this hypothesis using nearly 7,700 tissue samples obtained from prostate cancer patients. They discovered that the higher the BAZ2A levels in the tissue were, the more advanced the tumor was at the time of diagnosis, the more frequently it had already spread and formed metastases, and the higher patients' PSA levels were.
"BAZ2A seems to have a direct influence on the aggressiveness of prostate cancer," Plass says. "This suggests that levels of BAZ2A expression may serve as a valuable predictor of disease progression. Of course, this still needs to be clinically confirmed. Particularly in patients whose other clinical results indicate a medium risk, BAZ2A expression may provide important clues for the actual chances of recurrence. This would help physicians and patients choose the most promising treatment."
Source: Eurekalert
Advertisement
The researchers found the most obvious differences in the expression of a protein called BAZ2A. "The normal known function of this protein is to suppress factories that produce cellular proteins and thus affect the viability of cells," says Prof. Roland Eils, who leads a research group at both the DKFZ and at Heidelberg University. "But when we turned off BAZ2A in the cell lines of metastasizing prostate cancer, their growth was paradoxically slowed." Further studies showed that higher levels of BAZ2A increased specific malignant properties of prostate cancer cells, including their mobility and capacity to invade surrounding tissue. A detailed molecular analysis of prostate cancer cells showed that the overproduction of BAZ2A led to alterations in epigenetic patterns which then inhibited the activity of a number of cancer-suppressing genes. The scientists therefore suspected that the overexpression of BAZ2A might have a direct impact on the malignancy of prostate cancer and thus serve as a predictor for the course of the disease.
The team investigated this hypothesis using nearly 7,700 tissue samples obtained from prostate cancer patients. They discovered that the higher the BAZ2A levels in the tissue were, the more advanced the tumor was at the time of diagnosis, the more frequently it had already spread and formed metastases, and the higher patients' PSA levels were.
"BAZ2A seems to have a direct influence on the aggressiveness of prostate cancer," Plass says. "This suggests that levels of BAZ2A expression may serve as a valuable predictor of disease progression. Of course, this still needs to be clinically confirmed. Particularly in patients whose other clinical results indicate a medium risk, BAZ2A expression may provide important clues for the actual chances of recurrence. This would help physicians and patients choose the most promising treatment."
Source: Eurekalert
Foods That Boost Men's Health
Heart Disease and Cancer are the major killers for men above the age of 40. Cholesterol lowering through diet, lifestyle, and medications should be considered as the "real male multivitamin".
Advertisement
 Prostate Cancer Facts and FiguresProstate cancer is a cancer that forms in tissues of the prostate. It is the second most common cancer in men worldwide. | Advertisement
|
Advertisement
Recommended Reading
![Prostate Specific Antigen [PSA]](https://www.medindia.net/images/patientinfo/120x100/prostate-specific-antigen.jpg "Prostate Specific Antigen [PSA]")
Latest Cancer News
A new study assessed the association of cigarette smoking and vaping on cancer-related symptom burden (fatigue, pain, emotional problems) and quality of life.
Scientists are making strides in personalized breast cancer therapy by developing a highly accurate molecular classifier test for breast cancer patients.
Experts suggest high-income countries implement a comprehensive risk-based approach for prostate-specific antigen (PSA) testing to reduce overdiagnosis and overtreatment.
New study identifies the role of metabolic comorbidities such as obesity in contributing to the immunogenicity of oral cancer through the immune pathway STING-IFN-I.
Recent clinical trial results have shown that reducing the dose and duration of radiotherapy treatments for anal cancer may result in fewer side effects.